Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Gilead Sciences is conducting a Phase 2 study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC). The study aims to assess the efficacy of GS-1427 in achieving a clinical response in participants with moderate to severe ulcerative colitis by Week 12, compared to a placebo.
The intervention being tested is GS-1427, an oral drug designed to treat ulcerative colitis. The study involves different doses of GS-1427 and a placebo for comparison.
The study design is interventional, with a randomized, sequential intervention model. It employs double masking, meaning both participants and investigators are unaware of the treatment allocations, and its primary purpose is treatment.
The study began on March 27, 2024, with a primary completion date set for Week 12. The estimated overall completion is projected for Week 76, with the last update submitted on July 15, 2025.
This update could influence Gilead Sciences’ stock performance by potentially boosting investor confidence if the results are favorable. The study’s progress may also impact the competitive landscape in the ulcerative colitis treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.